NIKKEI 225
37,934.76 +306.28 (+0.81%) HANG SENG
17,708.71 +424.17 (+2.45%) CRUDE OIL
84.00 +0.43 (+0.51%) GOLD FUTURES
2,351.80 +9.30 (+0.40%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,528.73 +129.29 (+0.25%)
BioXcel Therapeutics, Inc. (BTAI)
After hours:
| Previous close | 2.7100 |
| Open | 2.7200 |
| Bid | 2.5600 x 100 |
| Ask | 2.6200 x 300 |
| Day's range | 2.5550 - 2.7200 |
| 52-week range | 1.9100 - 29.5600 |
| Volume | |
| Avg. volume | 1,547,837 |
| Market cap | 79.805M |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.1500 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.50 |
GlobeNewswireBioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET that day to discuss t
- GlobeNewswire
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that a late-breaking abstract with preliminary findings from the Phase 2 investigator-sponso
- GlobeNewswire
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No FDA-approved therapies for acute treatment of agitation associated with bipolar disorders or schizophrenia in the home setting NEW HAVEN, Conn., April 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced
